Drugs / 186RNL
186RNL
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07674693 | Jul 2026 → Jul 2028 expected | neoplastic meningitis | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07061626 | Sep 2025 → Mar 2027 expected | ependymoma, malignant glioma | Plus Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07098806 | Jul 2025 → Oct 2026 expected | neoplastic meningitis | Plus Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05460507 | Dec 2024 → Mar 2028 expected | glioma | Plus Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05034497 | Dec 2021 → Dec 2025 overdue | neoplastic meningitis | Plus Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 24
| Date | Issuer | Release |
|---|---|---|
| 2026-08-20 | Plus Therapeutics | Results Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines cerenome.com ↗
One presentation featured updated pharmacokinetic (PK), pharmacodynamic (PD), dosimetry, safety and activity data for REYOBIQ™ (rhenium-186 obisbemeda) in patients with leptomeningeal metastases (LM), including emerging safety data from the ongoing repeated-dosing program. |
| 2026-05-08 | Plus Therapeutics | Results Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases cerenome.com ↗ |
| 2026-04-08 | Plus Therapeutics | Regulatory Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas cerenome.com ↗
Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas. |
| 2025-12-04 | Plus Therapeutics | Results Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting cerenome.com ↗
Phase 1 ReSPECT-GBM showed promising improvements in overall survival |
| 2025-08-18 | Plus Therapeutics | Results Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases cerenome.com ↗
The data demonstrated treatment of leptomeningeal metastases (LM) with REYOBIQ is feasible, has a manageable safety profile, and shows a promising efficacy signal. |
| 2025-06-25 | Plus Therapeutics | Regulatory Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQ™ for the Treatment of Childhood Brain Cancer cerenome.com ↗ |
| 2025-05-14 | Plus Therapeutics | Results Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) cerenome.com ↗
This newly presented data shows safety, clinical benefit and data supporting the underlying mechanism of action for REYOBIQ in patients with Leptomeningeal Metastases, |
| 2025-04-15 | Plus Therapeutics | Results Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases cerenome.com ↗
Neuroimaging response data was available for 16 patients as of the data cutoff with five of those (31%) showing a partial response. |
| 2025-03-20 | Plus Therapeutics | Regulatory Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate cerenome.com ↗ |
| 2024-10-01 | Plus Therapeutics | Results Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting cerenome.com ↗
The data highlights the continued favorable safety profile and encouraging efficacy results of Rhenium ( 186 Re) Obisbemeda in a patient population with historically poor prognosis. |
| 2023-06-29 | Plus Therapeutics | Results Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting cerenome.com ↗
A single dose of rhenium ( 186 Re) obisbemeda was generally safe and well-tolerated, with no dose-limiting toxicities and minimal systemic radiation exposure. |
| 2022-11-19 | Plus Therapeutics | Results Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology cerenome.com ↗
Targeted radiotherapy using rhenium ( 186 Re) obisbemeda in patients with GBM and LM has, thus far, been shown to be both feasible and safe across a range of dosages and a variety of delivery parameters. |
| 2022-10-19 | Plus Therapeutics | Results Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress cerenome.com ↗
Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts |
| 2022-09-12 | Plus Therapeutics | Results Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 cerenome.com ↗
In the ReSPECT-GBM Phase 1 trial, we achieved up to 20 times the amount of radiation compared to external beam radiation therapy, and we observed a statistically significant improvement in survival in those patients receiving a therapeutic dose of radiation compared to those that did not. |
| 2022-08-13 | Plus Therapeutics | Results Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases cerenome.com ↗
Furthermore, all three patients in the cohort were observed to have prompt and complete 186 RNL distribution throughout the cerebrospinal fluid (CSF) subarachnoid space that was durable past one week and very well tolerated. |
| 2022-06-16 | Plus Therapeutics | Results Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial cerenome.com ↗
Patients seemed to tolerate 186 RNL infusions and the drug circulated completely and rapidly throughout the cebrebrospinal fluid space. |
| 2022-06-13 | Plus Therapeutics | Results Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting cerenome.com ↗
According to the interim data, 186 RNL delivered via convection enhanced delivery (CED) provides direct therapy with high radiation absorbed doses for local tumor control with minimal brain and whole-body radiation exposure. |
| 2021-11-18 | Plus Therapeutics | Results Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting cerenome.com ↗
According to the interim data, 186 RNL delivered via convection enhanced delivery (CED) is well-tolerated with favorable overall survival in adult patients at higher absorbed radiation doses (greater than 100 Gy). |
| 2021-11-09 | Plus Therapeutics | Regulatory Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases cerenome.com ↗ |
| 2021-10-27 | Plus Therapeutics | Results Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting cerenome.com ↗
Data demonstrated Rhenium-186 NanoLiposome ( 186 RNL) provides sustained, localized radiation treatment for over eight days to the tumor with minimal whole brain and body radiation exposure |
| 2021-10-19 | Plus Therapeutics | Regulatory Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases cerenome.com ↗ |
| 2021-08-21 | Plus Therapeutics | Results Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer cerenome.com ↗
Data shows that the administration of Rhenium-186 NanoLiposome ( 186 RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than with standard modalities |
| 2021-08-19 | Plus Therapeutics | Results Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial cerenome.com ↗ |
| 2021-08-11 | Plus Therapeutics | Results Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome cerenome.com ↗
Thus far, the therapy has been well tolerated with one possible treatment-related serious adverse event, cerebral edema, that resolved after steroid treatment. |
All press releases naming this drug 43 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 186RNL | “Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL), BMEDA-chelated-186rhenium encapsulated within liposomes, allows the 186Re to be directly delivered to the site of...” NCT07061626 ↗4“This Phase I clinical study evaluates a single dose of 186RNL (radionuclide clinical study drug) administered through a convection enhanced delivery catheter (CED catheter) in...” NCT05460507 ↗ |
| Known as | REYOBIQ | “Rhenium-186 NanoLiposome (186RNL, REYOBIQ)” NCT07674693 ↗ |
| Known as | Rhenium (186Re) Obisbemeda | “Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL), BMEDA-chelated-186rhenium encapsulated within liposomes, allows the 186Re to be directly delivered to the site of...” NCT07061626 ↗1“Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter” NCT07098806 ↗ |
| Known as | Rhenium-186 NanoLiposome | “Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter” NCT07098806 ↗ |
| Modality | Other / unclassified | “186RNL (radionuclide clinical study drug)” NCT05034497 ↗ |
| Route | Other | “via intraventricular catheter” NCT05034497 ↗ |